Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Lonza : Previews its Newest Clean Label Innovation - Vcaps plus White Opal, a Titanium Dioxide-Free Capsule

share with twitter share with LinkedIn share with facebook
share via e-mail
05/07/2019 | 07:19am EDT

Lonza today announces that its new Vcaps Plus White Opal capsule, which is designed to address the growing demand for opaque capsules that do not include titanium dioxide, is coming soon to the market.

By using an alternative opacifier, this new clean label capsule offers a natural semi-opaque look that masks unattractive food supplement ingredients. The new Vcaps Plus White Opal capsule will be presented next week at Vitafoods Europe 2019 in Geneva (CH), where Lonza is the Official Capsule Sponsor.

Demand for a Titanium Dioxide Alternative

Food-grade titanium dioxide, also known as E 171, is a common white pigment that has a long history of use in food supplement applications for its brightness and opacifying properties. However, recent scientific studies indicated potential risks associated with the presence of nanoparticles. Although the data is not conclusive and further research is needed, these findings question the justified use of nanoparticle titanium dioxide as a food additive. With strong ongoing public debate, the marketing of titanium dioxide-containing foodstuffs will be suspended in France beginning January 1, 2020.

As consumer awareness increases, supplement producers are seeking more natural alternatives that are free from titanium dioxide. Lonza's new Vcaps Plus White Opal capsule, the latest addition to its Capsugelrange of clean label plant-based capsules, is an ideal solution for supplement manufacturers.

Joachim Meier, Director, Head of Sales EMEA, Lonza Consumer Health & Nutrition, commented: 'With four out of five supplement users citing 'unquestionable safety' as a key decision-making factor when purchasing supplements, Lonza has developed the Vcaps Plus White Opal capsule as a high-quality, cutting-edge solution that meets evolving consumer preferences.

As a pioneer in vegetarian capsules with expertise in R&D, scale-up and the regulatory landscape, Lonza can help support supplement manufacturers in the development of innovative products with clean label benefits.'

Time for Color

Lonza will also be showcasing its expanding portfolio of clean label food colored capsules at Vitafoods, including the Vcaps Plus Blue Spirulina and Purple Carrot capsules and the soon-to-be launched Red Radish and Spicy Yellow. These next-generation capsules enable supplement brands to create vibrant products with colorful appeal, while also maintaining a natural appearance and delivering improved supply chain transparency.

Lonza is the Official Capsule Sponsor of Vitafoods Europe 2019. Lonza will be at booth G10, from 7-9 May, where attendees can talk to the experts or more information is available on www.capsugel.com

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum. Through our Lonza Pharma Biotech & Nutrition segment and our Lonza Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live. Founded in 1897 in the Swiss Alps, Lonza today is a wellrespected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion.


Dirk Oehlers

Tel: +41 61 316 8540

Email: dirk.oehlers@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on LONZA GROUP
08/15LONZA : Highlights Cutting-Edge Clean-Label Solutions to Welcome a Healthy Futur..
08/08LONZA : Welcomes Healthy Future for Brazilian Dietary Supplements Market at Fi S..
08/01Blue-blooded crabs at heart of pharma dispute on drug testing
07/24Lonza on Track to Deliver Full-Year 2019 Results, Driven by Pharma Biotech Bu..
07/24Lonza Expands Bioconjugation Facility and Announces Approval of Third Commerc..
07/11LONZA : Showcases Innovative Solutions to Make More Possible at the 14th Interna..
07/02LONZA : to Acquire Sterile Fill and Finish Facility from Novartis
07/01LONZA : Announces Short, Routine Shutdown of Niacinamide Plant in Nansha for Mai..
07/01Lonza fills portfolio hole by buying Novartis drug bottling plant
06/26LONZA : Launches the First in a Series of Educational Videos on 'Keeping Our Wor..
More news
Financials (CHF)
Sales 2019 5 915 M
EBIT 2019 1 206 M
Net income 2019 737 M
Debt 2019 3 284 M
Yield 2019 0,83%
P/E ratio 2019 35,6x
P/E ratio 2020 29,3x
EV / Sales2019 4,95x
EV / Sales2020 4,58x
Capitalization 26 008 M
Duration : Period :
Lonza Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 363,97  CHF
Last Close Price 350,30  CHF
Spread / Highest target 31,9%
Spread / Average Target 3,90%
Spread / Lowest Target -40,1%
EPS Revisions
Richard Ridinger Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP37.53%26 603
CELLTRION, INC.--.--%15 955